New! View global litigation for patent families

RU2004126182A - Device for analysis for forecasting and prediction method - Google Patents

Device for analysis for forecasting and prediction method

Info

Publication number
RU2004126182A
RU2004126182A RU2004126182A RU2004126182A RU2004126182A RU 2004126182 A RU2004126182 A RU 2004126182A RU 2004126182 A RU2004126182 A RU 2004126182A RU 2004126182 A RU2004126182 A RU 2004126182A RU 2004126182 A RU2004126182 A RU 2004126182A
Authority
RU
Grant status
Application
Patent type
Application number
RU2004126182A
Other languages
Russian (ru)
Inventor
Фил СТАУТ (US)
Фил СТАУТ
Тодд МЕЛАНДЕР (US)
Тодд МЕЛАНДЕР
Original Assignee
Лайфскен, Инк. (Us)
Лайфскен, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Detecting, measuring or recording for diagnostic purposes; Identification of persons
    • A61B5/0002Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Detecting, measuring or recording for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14532Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Detecting, measuring or recording for diagnostic purposes; Identification of persons
    • A61B5/15Devices for taking samples of blood
    • A61B5/150007Details
    • A61B5/150015Source of blood
    • A61B5/150022Source of blood for capillary blood or interstitial fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Detecting, measuring or recording for diagnostic purposes; Identification of persons
    • A61B5/15Devices for taking samples of blood
    • A61B5/150007Details
    • A61B5/150358Strips for collecting blood, e.g. absorbent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2560/00Constructional details of operational features of apparatus; Accessories for medical measuring apparatus
    • A61B2560/04Constructional details of apparatus
    • A61B2560/0431Portable apparatus, e.g. comprising a handle or case
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2562/00Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
    • A61B2562/02Details of sensors specially adapted for in-vivo measurements
    • A61B2562/0295Strip shaped analyte sensors for apparatus classified in A61B5/145 or A61B5/157
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Detecting, measuring or recording for diagnostic purposes; Identification of persons
    • A61B5/02Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A61B5/021Measuring pressure in heart or blood vessels
    • A61B5/022Measuring pressure in heart or blood vessels by applying pressure to close blood vessels, e.g. against the skin; Ophthalmodynamometers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Detecting, measuring or recording for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/1455Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Detecting, measuring or recording for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/1486Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using enzyme electrodes, e.g. with immobilised oxidase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Detecting, measuring or recording for diagnostic purposes; Identification of persons
    • A61B5/15Devices for taking samples of blood
    • A61B5/157Devices characterised by integrated means for measuring characteristics of blood
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Detecting, measuring or recording for diagnostic purposes; Identification of persons
    • A61B5/68Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
    • A61B5/6801Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
    • A61B5/6813Specially adapted to be attached to a specific body part
    • A61B5/6824Arm or wrist
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/11Automated chemical analysis

Claims (16)

1. Устройство для анализа для прогнозирования концентрации идентифицируемого соединения в цельной крови объекта, исходя из концентрации идентифицируемого соединения в интерстициальной жидкости объекта, содержащее модуль для набора образца интерстициальной жидкости для извлечения серии образцов интерстициальной жидкости (ISF) из объекта последовательным образом, модуль анализа для последовательного определения концентрации идентифицируемого соединения в ISF в каждом образце ISF в серии, и тем самым для создания серий концентраций идент 1. A device for the analysis to predict the concentration of compounds identified in whole blood of the object, based on the concentration of the compound identified object in the interstitial fluid, comprising a set module for interstitial fluid extraction of a sample for a series of samples of interstitial fluid (ISF) from the object in a sequential manner, analysis module for sequentially determining the concentration of an identified compound in the ISF ISF in each sample in a series, and thus to create a series of ident concentrations ифицируемого соединения в ISF, и модуль прогнозирования для сохранения серий концентраций идентифицируемого соединения в ISF и прогнозирования концентрации идентифицируемого соединения в цельной крови объекта на основе серий концентраций идентифицируемого соединения в ISF посредством выполнения, по меньшей мере, одного алгоритма в следующей общей форме: ifitsiruemogo compound as ISF, and prediction unit for storing an identified series concentrations of compound and ISF prediction identified compound concentration in the whole blood of the object on the basis of a series of compounds identified in ISF concentrations by performing at least one algorithm of the following general form:
PC=f(ISF i k , rate j , significant interaction terms), PC = f (ISF i k, rate j, significant interaction terms),
где PC - спрогнозированная концентрация идентифицируемого соединения в цельной крови объекта; where PC - the predicted concentration of a compound identifiable in whole blood of the object;
i - целое число с предопределенным значением, выбираемым из значений 0, 1, 2, 3, 4 и 5; i - a predetermined integer value selected from the values ​​0, 1, 2, 3, 4 and 5;
j - целое число с предопределенным значением, выбираемым из значений 1, 2, 3, 4 и 5; j - an integer with predetermined values ​​selected from the values ​​1, 2, 3, 4 and 5;
k - целое число с предопределенным значением, выбираемым из значений 1 и 2; k - a predetermined integer value selected from the values ​​1 and 2;
ISF i - измеренная концентрация идентифицируемого соединения в ISF в сериях концентраций идентифицируемого соединения в ISF; ISF i - measured concentration of the identified compound in a series of ISF identified compound concentrations in the ISF;
rate j - скорость изменения между непосредственно смежными концентрациями идентифицируемого соединения в ISF в сериях концентраций идентифицируемого соединения в ISF; rate j - rate of change between immediately adjacent concentrations identified compound in a series of ISF identified compound concentrations in the ISF; и and
significant interaction terms - статистически значимые слагаемые, учитывающие взаимодействия, включающие слагаемые, выбранные из группы, состоящей из ISF i k и rate j . significant interaction terms - statistically significant terms, taking into account the interactions involving terms selected from the group consisting of ISF i k and rate j.
2. Устройство по п.1, в котором i=0, k=1, j=2, 3, 4 и 5, и слагаемые, учитывающие взаимодействия - rate 2 *rate 1 , rate 1 *rate 3 , rate 2 *rate 4 , и rate 2 *rate 2 *rate 4 . 2. The apparatus of claim 1, wherein i = 0, k = 1, j = 2, 3, 4 and 5, and the terms, taking into account interaction - rate 2 * rate 1, rate 3 1 * rate, rate 2 * rate 4, and 2 * rate rate rate 2 * 4.
3. Устройство по п.1, в котором идентифицируемым соединением является глюкоза. 3. The apparatus of claim 1, wherein the compound is identifiable glucose.
4. Устройство по п.1, в котором прогнозирование концентрации идентифицируемого соединения в цельной крови объекта основано на сериях концентраций идентифицируемого соединения в ISF посредством выполнения, по меньшей мере, одного алгоритма в следующей общей форме: 4. The apparatus of claim 1, wherein the prediction of the concentration of a compound identifiable in whole blood of the object based on a series of identified compounds in ISF concentrations by performing at least one algorithm of the following general form:
PC=f(ISF i k , rate j , ma n rate m p , significant interaction terms), PC = f (ISF i k, rate j, ma n rate m p, significant interaction terms),
где p - целое число с предопределенным значением, выбираемым из значений 1 и 2; where p - an integer with predetermined values ​​selected from the values ​​1 and 2;
n и m - целые числа с предопределенными значениями, выбираемыми из значений 1, 2 и 3; n and m - are integers with predetermined values ​​selected from the values ​​1, 2 and 3;
ma n rate m - скользящее среднее скорости между непосредственно смежными средними значениями групп величин ISF; ma n rate m - moving average rate between adjacent averages directly groups quantities ISF; и and
significant interaction terms - статистически значимые слагаемые, учитывающие взаимодействия, включающие слагаемые, выбранные из группы, состоящей из ISF i k , rate j , и ma n rate m p . significant interaction terms - statistically significant terms, taking into account the interactions involving terms selected from the group consisting of ISF i k, rate j, and ma n rate m p.
5. Устройство по п.4, в котором модуль прогнозирования выполнен с возможностью прогнозирования концентрации идентифицируемого соединения в цельной крови объекта, определение, являются ли серии концентраций идентифицируемого соединения в ISF возрастающими концентрациями идентифицируемого соединения в ISF или убывающими концентрациями идентифицируемого соединения в ISF, выбора алгоритма на основе этого определения, и применения выбранного алгоритма. 5. The apparatus of claim 4, wherein the prediction unit configured to predict the concentration of compounds identified in whole blood of the object, determining whether the identified series of compounds in ISF concentrations increasing concentrations identified compound as ISF or decreasing concentrations of the compounds identified in ISF, the selection algorithm based on that determination, and applying the selected algorithm.
6. Устройство по п.5, в котором модуль прогнозирования выполнен с возможностью прогнозирования концентрации идентифицируемого соединения в цельной крови объекта, определения, являются ли серии концентраций идентифицируемого соединения в ISF возрастающими концентрациями идентифицируемого соединения в ISF или убывающими концентрациями идентифицируемого соединения в ISF на основании ma n rate m . 6. The apparatus of claim 5, wherein the prediction unit configured to predict the concentration of compounds identified in whole blood of the object, determining whether the identified series of compounds in ISF concentrations increasing concentrations identified compound as ISF or decreasing concentrations of the compounds identified in ISF based ma n rate m.
7. Устройство по п.6, в котором алгоритм, применяемый к убывающей концентрации идентифицируемого соединения в ISF есть 7. The apparatus of claim 6, wherein the algorithm is applied to a decreasing concentration in the ISF identified compound is
Figure 00000001
8. Устройство по п.6, в котором алгоритм, применяемый к возрастающей концентрации идентифицируемого соединения в ISF есть 8. The apparatus of claim 6, wherein the algorithm is applied to an increasing concentration in the ISF identified compound is
Figure 00000002
9. Устройство по п.4, в котором идентифицируемым соединением является глюкоза. 9. The apparatus of claim 4, wherein the identifiable compound is glucose.
10. Устройство по п.1, в котором серии концентраций идентифицируемого соединения в ISF включают в себя пять концентраций идентифицируемого соединения в ISF. 10. The apparatus of claim 1, wherein the series of identified compounds in ISF concentrations include concentrations of five compounds identified in the ISF.
11. Устройство по п.1, в котором модуль для набора образца выполнен с возможностью извлечения группы образцов ISF с временными интервалами в диапазоне от пяти до пятнадцати минут. 11. The apparatus of claim 1, wherein the sample set unit is configured to extract groups of ISF samples at time intervals ranging from five to fifteen minutes.
12. Способ прогнозирования концентрации идентифицируемого соединения в цельной крови объекта, исходя из концентрации идентифицируемого соединения в интерстициальной жидкости объекта, состоящий в том, что извлекают серии образцов интерстициальной жидкости (ISF) из объекта последовательным образом, последовательно определяют концентрацию идентифицируемого соединения в ISF в каждом образце ISF в серии, и тем самым создают серии концентраций идентифицируемого соединения в ISF, и прогнозируют концентрацию идентифицируемого соединения в цельн 12. A method of predicting the concentration of a compound identifiable in whole blood of the object, based on the concentration of the compound identified object in the interstitial fluid, which consists in that a series of interstitial fluid recovered samples (ISF) from the object in a sequential manner, sequentially, the concentration of the identified compound in each sample ISF ISF in series, and thus create a series of compound concentrations identified in ISF, and predict the concentration of compounds identified in whole й крови объекта на основе серий концентраций идентифицируемого соединения в ISF посредством выполнения, по меньшей мере, одного алгоритма в следующей форме: th object based on blood series identified compounds in ISF concentrations by performing at least one algorithm of the following form:
PC=f(ISF i k , rate j , significant interaction terms), PC = f (ISF i k, rate j, significant interaction terms),
где PC - спрогнозированная концентрация идентифицируемого соединения в цельной крови объекта; where PC - the predicted concentration of a compound identifiable in whole blood of the object;
i - целое число с предопределенным значением, выбираемым из значений 0, 1, 2, 3, 4 и 5; i - a predetermined integer value selected from the values ​​0, 1, 2, 3, 4 and 5;
j - целое число с предопределенным значением, выбираемым из значений 1, 2, 3, 4 и 5; j - an integer with predetermined values ​​selected from the values ​​1, 2, 3, 4 and 5;
k - целое число с предопределенным значением, выбираемым из значений 1 и 2; k - a predetermined integer value selected from the values ​​1 and 2;
ISF i - измеренная концентрация идентифицируемого соединения в ISF в сериях концентраций идентифицируемого соединения в ISF; ISF i - measured concentration of the identified compound in a series of ISF identified compound concentrations in the ISF;
rate j - скорость изменения между непосредственно смежными концентрациями идентифицируемого соединения в ISF в сериях концентраций идентифицируемого соединения в ISF; rate j - rate of change between immediately adjacent concentrations identified compound in a series of ISF identified compound concentrations in the ISF; и and
significant interaction terms - статистически значимые слагаемые, учитывающие взаимодействия, включающие слагаемые, выбранные из группы состоящей из ISF i k и rate j . significant interaction terms - statistically significant terms, taking into account the interactions involving terms selected from the group consisting of ISF i k and rate j.
13. Способ по п.12, в котором блок прогнозирования применяет алгоритм в форме 13. The method of claim 12, wherein the predicting unit uses the algorithm in the form of
PC=f(ISF i k , rate j , ma n rate m p , significant interaction terms), PC = f (ISF i k, rate j, ma n rate m p, significant interaction terms),
где p - целое число с предопределенным значением, выбираемым из значений 1 и 2; where p - an integer with predetermined values ​​selected from the values ​​1 and 2;
m и n - целые числа с предопределенными значениями, выбираемыми из значений 1, 2 и 3; m and n - integers with predetermined values ​​selected from the values ​​1, 2 and 3;
ma n rate m - скользящее среднее скорости между непосредственно смежными средними значениями групп величин ISF; ma n rate m - moving average rate between adjacent averages directly groups quantities ISF; и and
significant interaction terms - статистически значимые слагаемые, учитывающие взаимодействия, включающие слагаемые, выбранные из группы, состоящей из ISF i k , rate j , и ma n rate m p . significant interaction terms - statistically significant terms, taking into account the interactions involving terms selected from the group consisting of ISF i k, rate j, and ma n rate m p.
14. Способ по п.13, в котором на этапе прогнозирования прогнозируют концентрацию идентифицируемого соединения в цельной крови объекта при помощи определения, являются ли серии концентраций идентифицируемого соединения в ISF возрастающими концентрациями идентифицируемого соединения в ISF или убывающими концентрациями идентифицируемого соединения в ISF, выбора алгоритма на основе этого определения, и применения выбранного алгоритма. 14. The method of claim 13, wherein the step of predicting predicts the concentration of a compound identifiable in whole blood of the object by determining whether an identified series concentrations of compound ISF increasing concentrations identified compound as ISF or decreasing concentrations of the compounds identified in ISF, the selection algorithm based on this determination, and applying the selected algorithm.
15. Способ по п.13, в котором на этапе прогнозирования прогнозируют концентрацию идентифицируемого соединения в цельной крови объекта при помощи определения, являются ли серии концентраций идентифицируемого соединения в ISF возрастающими концентрациями идентифицируемого соединения в ISF или убывающими концентрациями идентифицируемого соединения в ISF на основе ma n rate m . 15. The method of claim 13, wherein the step of predicting predicts the concentration of a compound identifiable in whole blood of the object by determining whether an identified series concentrations of compound ISF increasing concentrations identified compound as ISF or decreasing concentrations of the compounds identified in ISF based ma n rate m.
16. Способ по п.12, в котором на этапе извлечения группу образцов ISF извлекают из дермиса объекта. 16. The method of claim 12, wherein the step of extracting ISF sample group is extracted from the dermis of the object.
RU2004126182A 2003-06-06 2004-08-27 Device for analysis for forecasting and prediction method RU2004126182A (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US10/652,464 2003-08-28
US10653023 US7258673B2 (en) 2003-06-06 2003-08-28 Devices, systems and methods for extracting bodily fluid and monitoring an analyte therein
US10652464 US20040253736A1 (en) 2003-06-06 2003-08-28 Analytical device with prediction module and related methods
US10/653,023 2003-08-28

Publications (1)

Publication Number Publication Date
RU2004126182A true true RU2004126182A (en) 2006-02-10

Family

ID=34108168

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2004126182A RU2004126182A (en) 2003-06-06 2004-08-27 Device for analysis for forecasting and prediction method

Country Status (7)

Country Link
US (1) US20040253736A1 (en)
EP (1) EP1510171A1 (en)
JP (1) JP2005077412A (en)
KR (1) KR20050021955A (en)
CN (1) CN1644163A (en)
CA (1) CA2479107A1 (en)
RU (1) RU2004126182A (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8465425B2 (en) 1998-04-30 2013-06-18 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9066695B2 (en) 1998-04-30 2015-06-30 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8346337B2 (en) 1998-04-30 2013-01-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8480580B2 (en) 1998-04-30 2013-07-09 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8688188B2 (en) 1998-04-30 2014-04-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8974386B2 (en) 1998-04-30 2015-03-10 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6175752B1 (en) 1998-04-30 2001-01-16 Therasense, Inc. Analyte monitoring device and methods of use
US6560471B1 (en) 2001-01-02 2003-05-06 Therasense, Inc. Analyte monitoring device and methods of use
WO2002078512A8 (en) 2001-04-02 2004-12-02 Therasense Inc Blood glucose tracking apparatus and methods
US7993108B2 (en) 2002-10-09 2011-08-09 Abbott Diabetes Care Inc. Variable volume, shape memory actuated insulin dispensing pump
US7727181B2 (en) 2002-10-09 2010-06-01 Abbott Diabetes Care Inc. Fluid delivery device with autocalibration
CA2501825C (en) 2002-10-09 2009-12-01 Therasense, Inc. Fluid delivery device, system and method
US7811231B2 (en) 2002-12-31 2010-10-12 Abbott Diabetes Care Inc. Continuous glucose monitoring system and methods of use
US6949816B2 (en) 2003-04-21 2005-09-27 Motorola, Inc. Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same
US7679407B2 (en) 2003-04-28 2010-03-16 Abbott Diabetes Care Inc. Method and apparatus for providing peak detection circuitry for data communication systems
US8066639B2 (en) 2003-06-10 2011-11-29 Abbott Diabetes Care Inc. Glucose measuring device for use in personal area network
US8771183B2 (en) 2004-02-17 2014-07-08 Abbott Diabetes Care Inc. Method and system for providing data communication in continuous glucose monitoring and management system
US20060036187A1 (en) 2004-06-30 2006-02-16 Hester Vos Devices, systems and methods for extracting bodily fluid and monitoring an analyte therein
EP1863559A4 (en) 2005-03-21 2008-07-30 Abbott Diabetes Care Inc Method and system for providing integrated medication infusion and analyte monitoring system
US8112240B2 (en) 2005-04-29 2012-02-07 Abbott Diabetes Care Inc. Method and apparatus for providing leak detection in data monitoring and management systems
US7768408B2 (en) 2005-05-17 2010-08-03 Abbott Diabetes Care Inc. Method and system for providing data management in data monitoring system
US7620437B2 (en) 2005-06-03 2009-11-17 Abbott Diabetes Care Inc. Method and apparatus for providing rechargeable power in data monitoring and management systems
US20070038148A1 (en) * 2005-08-11 2007-02-15 Joel Mechelke Sampling module for extracting interstitial fluid
US20070060844A1 (en) * 2005-08-29 2007-03-15 Manuel Alvarez-Icaza Applied pressure sensing cap for a lancing device
US7756561B2 (en) 2005-09-30 2010-07-13 Abbott Diabetes Care Inc. Method and apparatus for providing rechargeable power in data monitoring and management systems
US7583190B2 (en) 2005-10-31 2009-09-01 Abbott Diabetes Care Inc. Method and apparatus for providing data communication in data monitoring and management systems
US7766829B2 (en) 2005-11-04 2010-08-03 Abbott Diabetes Care Inc. Method and system for providing basal profile modification in analyte monitoring and management systems
US8344966B2 (en) 2006-01-31 2013-01-01 Abbott Diabetes Care Inc. Method and system for providing a fault tolerant display unit in an electronic device
US8226891B2 (en) 2006-03-31 2012-07-24 Abbott Diabetes Care Inc. Analyte monitoring devices and methods therefor
US7620438B2 (en) 2006-03-31 2009-11-17 Abbott Diabetes Care Inc. Method and system for powering an electronic device
US20080071157A1 (en) 2006-06-07 2008-03-20 Abbott Diabetes Care, Inc. Analyte monitoring system and method
US8579853B2 (en) 2006-10-31 2013-11-12 Abbott Diabetes Care Inc. Infusion devices and methods
US8732188B2 (en) 2007-02-18 2014-05-20 Abbott Diabetes Care Inc. Method and system for providing contextual based medication dosage determination
US8930203B2 (en) 2007-02-18 2015-01-06 Abbott Diabetes Care Inc. Multi-function analyte test device and methods therefor
US8123686B2 (en) 2007-03-01 2012-02-28 Abbott Diabetes Care Inc. Method and apparatus for providing rolling data in communication systems
US8665091B2 (en) 2007-05-08 2014-03-04 Abbott Diabetes Care Inc. Method and device for determining elapsed sensor life
US7928850B2 (en) 2007-05-08 2011-04-19 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8461985B2 (en) 2007-05-08 2013-06-11 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8456301B2 (en) 2007-05-08 2013-06-04 Abbott Diabetes Care Inc. Analyte monitoring system and methods
GB0800981D0 (en) * 2008-01-18 2008-02-27 Plaque Attack Ltd Catheter
RU2508899C2 (en) * 2008-02-27 2014-03-10 Мон4Д Лтд. Device, system and method for modular analyte test
US20110160555A1 (en) * 2008-07-31 2011-06-30 Jacques Reifman Universal Models for Predicting Glucose Concentration in Humans
US8103456B2 (en) 2009-01-29 2012-01-24 Abbott Diabetes Care Inc. Method and device for early signal attenuation detection using blood glucose measurements
US8560082B2 (en) 2009-01-30 2013-10-15 Abbott Diabetes Care Inc. Computerized determination of insulin pump therapy parameters using real time and retrospective data processing
WO2010129375A1 (en) 2009-04-28 2010-11-11 Abbott Diabetes Care Inc. Closed loop blood glucose control algorithm analysis
WO2010127050A1 (en) 2009-04-28 2010-11-04 Abbott Diabetes Care Inc. Error detection in critical repeating data in a wireless sensor system
EP2456351B1 (en) 2009-07-23 2016-10-12 Abbott Diabetes Care, Inc. Real time management of data relating to physiological control of glucose levels
EP2473098A4 (en) 2009-08-31 2014-04-09 Abbott Diabetes Care Inc Analyte signal processing device and methods
EP2473099A4 (en) 2009-08-31 2015-01-14 Abbott Diabetes Care Inc Analyte monitoring system and methods for managing power and noise
EP2482720A4 (en) 2009-09-29 2014-04-23 Abbott Diabetes Care Inc Method and apparatus for providing notification function in analyte monitoring systems
WO2011105178A1 (en) * 2010-02-26 2011-09-01 アークレイ株式会社 Analysis device, analysis method, and analysis system
GB2502287B (en) * 2012-05-21 2016-11-23 Dermal Diagnostics Ltd Cumulative measurement of an analyte
EP3089667A4 (en) * 2014-01-31 2017-09-13 Univ Boston Offline glucose control based on preceding periods

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5002054A (en) * 1987-02-25 1991-03-26 Ash Medical Systems, Inc. Interstitial filtration and collection device and method for long-term monitoring of physiological constituents of the body
NL8702370A (en) * 1987-10-05 1989-05-01 Groningen Science Park A method and system for determination of glucose and therefor useful meetcelsamenstel.
US5139023A (en) * 1989-06-02 1992-08-18 Theratech Inc. Apparatus and method for noninvasive blood glucose monitoring
US6040194A (en) * 1989-12-14 2000-03-21 Sensor Technologies, Inc. Methods and device for detecting and quantifying substances in body fluids
US5231975A (en) * 1990-02-23 1993-08-03 Cygnus Therapeutic Systems Ultrasound-enhanced delivery of materials into and through the skin
US5593852A (en) * 1993-12-02 1997-01-14 Heller; Adam Subcutaneous glucose electrode
US5795325A (en) * 1991-07-16 1998-08-18 Heartport, Inc. Methods and apparatus for anchoring an occluding member
US5165418B1 (en) * 1992-03-02 1999-12-14 Nikola I Tankovich Blood sampling device and method using a laser
US5582184A (en) * 1993-10-13 1996-12-10 Integ Incorporated Interstitial fluid collection and constituent measurement
US5458140A (en) * 1993-11-15 1995-10-17 Non-Invasive Monitoring Company (Nimco) Enhancement of transdermal monitoring applications with ultrasound and chemical enhancers
US6240306B1 (en) * 1995-08-09 2001-05-29 Rio Grande Medical Technologies, Inc. Method and apparatus for non-invasive blood analyte measurement with fluid compartment equilibration
US5879367A (en) * 1995-09-08 1999-03-09 Integ, Inc. Enhanced interstitial fluid collection
US5706806A (en) * 1996-04-26 1998-01-13 Bioanalytical Systems, Inc. Linear microdialysis probe with support fiber
DE19618597B4 (en) * 1996-05-09 2005-07-21 Institut für Diabetestechnologie Gemeinnützige Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm A method for determining the concentration of tissue glucose
US6332871B1 (en) * 1996-05-17 2001-12-25 Amira Medical Blood and interstitial fluid sampling device
US6234990B1 (en) * 1996-06-28 2001-05-22 Sontra Medical, Inc. Ultrasound enhancement of transdermal transport
US5956501A (en) * 1997-01-10 1999-09-21 Health Hero Network, Inc. Disease simulation system and method
US6558321B1 (en) * 1997-03-04 2003-05-06 Dexcom, Inc. Systems and methods for remote monitoring and modulation of medical devices
US5951493A (en) * 1997-05-16 1999-09-14 Mercury Diagnostics, Inc. Methods and apparatus for expressing body fluid from an incision
DE69839149D1 (en) * 1997-06-04 2008-04-03 Sensor Technologies Inc Method and apparatus for detecting or quantifying of carbohydrates containing compounds
CA2294610A1 (en) * 1997-06-16 1998-12-23 George Moshe Katz Methods of calibrating and testing a sensor for in vivo measurement of an analyte and devices for use in such methods
US6468229B1 (en) * 1998-10-20 2002-10-22 Abbott Laboratories Apparatus and method for the collection of interstitial fluids
US6706000B2 (en) * 1997-11-21 2004-03-16 Amira Medical Methods and apparatus for expressing body fluid from an incision
US5964718A (en) * 1997-11-21 1999-10-12 Mercury Diagnostics, Inc. Body fluid sampling device
US6155992A (en) * 1997-12-02 2000-12-05 Abbott Laboratories Method and apparatus for obtaining interstitial fluid for diagnostic tests
US6022316A (en) * 1998-03-06 2000-02-08 Spectrx, Inc. Apparatus and method for electroporation of microporated tissue for enhancing flux rates for monitoring and delivery applications
DE69910007D1 (en) * 1998-05-13 2003-09-04 Cygnus Therapeutic Systems Apparatus for predicting physiological measuring values
DE69914319D1 (en) * 1998-05-13 2004-02-26 Cygnus Therapeutic Systems Signal processing for measurement of physiological analytes
EP1102559B1 (en) * 1998-09-30 2003-06-04 Cygnus, Inc. Method and device for predicting physiological values
DE60045351D1 (en) * 1999-02-04 2011-01-20 Integ Inc Needle body fluid tester
US6424847B1 (en) * 1999-02-25 2002-07-23 Medtronic Minimed, Inc. Glucose monitor calibration methods
JP3594534B2 (en) * 1999-04-30 2004-12-02 ヘルマン ファウ、リリエンフェルトアル Apparatus for detecting a substance
DE19935165A1 (en) * 1999-07-28 2001-02-01 Roche Diagnostics Gmbh Method and arrangement for determining the concentration of glucose in a body fluid
WO2001019880A9 (en) * 1999-09-13 2001-08-30 Asahi Glass Co Ltd Tetrafluoroethylene / ethylene copolymer and film thereof
CN1198536C (en) * 1999-12-28 2005-04-27 平迪产品公司 Method and apparatus for non-invasive analysis of blood glucose
US6477392B1 (en) * 2000-07-14 2002-11-05 Futrex Inc. Calibration of near infrared quantitative measurement device using optical measurement cross-products
WO2002024065A1 (en) * 2000-09-22 2002-03-28 Knobbe, Lim & Buckingham Method and apparatus for real-time estimation and control of pysiological parameters
GB0030929D0 (en) * 2000-12-19 2001-01-31 Inverness Medical Ltd Analyte measurement
US6549796B2 (en) * 2001-05-25 2003-04-15 Lifescan, Inc. Monitoring analyte concentration using minimally invasive devices
US6501976B1 (en) * 2001-06-12 2002-12-31 Lifescan, Inc. Percutaneous biological fluid sampling and analyte measurement devices and methods
US6702857B2 (en) * 2001-07-27 2004-03-09 Dexcom, Inc. Membrane for use with implantable devices
WO2003030731A3 (en) * 2001-10-09 2003-12-04 James R Braig Method and apparatus for improving clinical accuracy of analyte measurements
US6966880B2 (en) * 2001-10-16 2005-11-22 Agilent Technologies, Inc. Universal diagnostic platform
US20030212344A1 (en) * 2002-05-09 2003-11-13 Vadim Yuzhakov Physiological sample collection devices and methods of using the same
EP2260759B1 (en) * 2005-06-17 2015-05-06 F. Hoffmann-La Roche AG Sensor system, arrangement and method for monitoring a compound, in particular glucose in body tissue.

Also Published As

Publication number Publication date Type
KR20050021955A (en) 2005-03-07 application
CA2479107A1 (en) 2005-02-28 application
US20040253736A1 (en) 2004-12-16 application
CN1644163A (en) 2005-07-27 application
EP1510171A1 (en) 2005-03-02 application
JP2005077412A (en) 2005-03-24 application

Similar Documents

Publication Publication Date Title
RU2003118800A (en) Rangedifference method pelegovaniya radio source and implementing its device
RU2006118699A (en) The image encoding apparatus and method for predicting shear using rotation matching
RU37244U1 (en) The information-analytical system for the simulation and evaluation of the company
RU2006126660A (en) Moving image encoding apparatus, the method and the device management program
RU2005113995A (en) Device binding method
RU2003128051A (en) Magnesium-zirconium sponge producing method and device for its realization
RU2003120424A (en) A method of determining the gas composition and the device for its realization
RU2005108921A (en) block prediction method using improved direct mode
RU2003103433A (en) The method and apparatus of the induction bottom drain
RU2003120392A (en) A method for agriculture and device for its realization
RU2007111490A (en) Method and device for the window information virtualization
RU2003105718A (en) Method coating pipe and device for its embodiment (variants)
RU2003130421A (en) A method for diagnosing functional and pathologic processes in the human or animal
RU2006101860A (en) Time recording system and method for registering the working time
RU2005105559A (en) The method and apparatus for electrolysis
RU2006140246A (en) Methods and apparatus for phase-input system in action
RU2005127419A (en) A method and apparatus for enhancing speech using multiple sensors
RU2006120562A (en) Combination printing method and device for its realization
DE602004009906D1 (en) Analytical method and kit for
RU2003125942A (en) Method pereraboki rubber waste
RU2006127441A (en) Ion exchange dental device and method
DE602004027821D1 (en) Sorting apparatus and method
RU2003122015A (en) Container Sampler
DE60325184D1 (en) Rs7 antibody
RU2004130811A (en) The information processing system and information processing method

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20090120